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Research Article
Separation and determination of alpha-
synuclein monomeric and oligomeric
species using two electrophoretic
approaches
Parkinson’s disease (PD) is a frequent degenerative disorder that is diagnosed based on
clinical symptoms. When the first symptoms appear, more than 70% of the dopaminergic
cells are already lost. Therefore, it is of utmost importance to have reliable biomarkers
to diagnose much earlier PD. In this context, alpha-synuclein (aSyn) is a protein of high
interest because of its tendency to form oligomers and amyloid fibrils. The oligomeric
forms seem to play a critical pathological role in PD. To date, most of studies aiming at
detecting and quantifying aSyn oligomers were performed by immunoassays, mainly by
ELISA using specific antibodies. In this study a capillary gel electrophoresis (CGE) coupled
with fluorescence detection method was developed to detect and quantify the oligomeric
forms of aSyn formed in vitro. All the results obtained were supported by SDS–PAGE
analysis, a widely used and well-known technique but exhibiting a main drawback since
it is not an automated technique. The repeatability and the intermediate precision of
the method were evaluated, as well as the stability of the labeled and non-labeled aSyn
samples. After careful screening and optimization of various labeling reagents, 4-fluoro-
7-nitrobenzofurazan (NBD-F) was selected and used to establish a calibration curve with
monomeric fluorescently-labeled aSyn. Finally, the method was used to study the effect of
doxycycline on the oligomerization process. Altogether, our results show that CGE is a very
promising automated technique to analyze aSyn monomers, as well as small oligomers.
Keywords:
aSyn / CGE / Labeling / SDS–PAGE DOI 10.1002/elps.201800224
 Additional supporting information may be found online in the Supporting Infor-mation section at the end of the article.
1 Introduction
Parkinson’s disease (PD) is a frequent movement disorder,
the second most common adult-onset degenerative disease
of the central nervous system. Initially, the disease was de-
scribed by James Parkinson in the “Essay on the shaking
palsy” (1817), in which he reported the major motor symp-
toms of PD, that are the hallmarks of the disease: bradyki-
nesia, rigidity and tremor [1]. In the absence of validated
Correspondence: Prof. Marianne Fillet, Laboratory for the Analy-
sis of Medicines, Department of Pharmacy, Faculty of Medicine,
CIRM, University of Lie`ge, Avenue de I’Hopital, 1, B36 +3, Tower
4, 4000 Lie`ge, Belgium
Fax: +32 4 3664347
E-mail: marianne.fillet@uliege.be
Abbreviations: aSyn, alpha-synuclein; BMs, biomarkers;
CGE, capillary gel electrophoresis; CSF, cerebrospinal fluid;
MW, molecular weight; PD, Parkinson’s disease
diagnostic biomarker, PD diagnosis remains clinical but
this approach suffers from a lack of specificity to discrimi-
nate patients with PD from normal aging, people with non-
parkinsonian tremor, or those presenting with a parkinso-
nian syndrome not caused by PD. Because of the overlapping
clinical features, the differential diagnosis between these con-
ditions is difficult on clinical grounds, especially in the early
stages. Another important drawback of the clinical diagno-
sis is that 50% of the dopaminergic neurons are already lost
when the first symptoms appear. Even if PD is the center of
much attention to find one or multiple biomarkers (BMs),
no validated marker is available until now. In the context of
PD, this would be of tremendous importance for different
reasons. First, one or more reliable BMs would provide an
earlier and more accurate diagnosis of the disease, leading
to a better and earlier treatment, even before the emergence
of the first symptoms. Second, BMs would be very useful
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in clinical trials, as they would allow one to test the efficacy
of different treatments. Third, they would also be helpful to
monitor objectively the disease progression [2].
Synucleinopathies, including PD, are mainly char-
acterized by the accumulation and the deposition of
alpha-synuclein (aSyn) protein into amyloid fibrils. These de-
posits form inclusions called Lewy Bodies are present mainly
in neurons and glial cells. aSyn is a small acidic protein,
constituted of 140 amino acid residues. aSyn, together with
beta- and gamma–synuclein, constitute the family of synu-
cleins. aSyn is physiologically expressed at high level in the
central nervous system under a monomeric form, but it can
also be detected in the periphery. The physiological function
of aSyn remains unclear, but it may play a role in neuronal
plasticity [3] and in normal SNARE-complex assembly [4].
The primary structure of aSyn is characterized by three
distinct regions, the amphiphatic N-terminal region (1-60),
the central NAC region (61-95) and the acidic C-terminal
region (96-140). The NAC region is extremely hydrophobic
and it forms the core of the deposited fibrils. The aggregation
pathway of aSyn into amyloid fibrils is complex and involves
the formation of various species including oligomers,
protofibrils and fibrils. In vitro and in vivo studies support
the hypothesis that prefibrillar oligomers constitute the toxic
species of aSyn [5, 6]. Therefore, intensive researches are
currently performed to characterize the properties of these
species (structure, toxicity, . . . ) at the molecular level and,
to detect and quantify them in vitro or in peripheral fluids.
Total aSyn levels measurements are based on im-
munoassay platforms, and the most widely applied ELISA
method allows the quantification of total aSyn levels, with
a detection limit of down to 1 pg/mL [2, 7]. Few studies
quantifying specifically the oligomeric species of aSyn in
cerebrospinal fluid (CSF) and peripheral fluids were also
performed [8–15]. Nevertheless, across all these studies, dif-
ferences in the measured levels are likely to be related to dif-
ferent analytical procedures, from sample collection to sam-
ple processing [16], which clearly demonstrates a real and
urgent need for procedure standardization. To avoid such
discrepancies in the results, a number of important peri-
analytical considerations have to be taken into account when
quantifying this protein in different biofluids [17, 18]. These
considerations correspond to variables which are important
to take into account during a biomarker study in PD (based
on immunoassay), and more especially for the quantifica-
tion of total aSyn protein, like the addition of detergent,
the aliquot volume, the temperature of sample collection,
etc.
ELISA and other immunoassay techniques are well
known and very sensitive, but several factors can affect the
signal, thus causing bias in biomarker measurements [2].
These factors include the interference of endogenous perox-
idase and heterophilic antibodies, a lack of standardization
for the reference peptides, or the competition of monomers
for the detection of oligomers during in vivo or in vitro as-
says [7, 19–21]. Moreover, variations in the signal intensity
can be observed depending on the detected species, as ELISA
gives higher signal for the oligomeric forms compared to the
monomeric forms. The development of another methodol-
ogy taking into account the challenges described above would
provide a complementary approach to quantify aSyn and its
different oligomeric forms.
Over the last decades, SDS–CGE, also called CGE has
become a powerful technique for protein analyses. Nowadays
CGEmethods are used daily in biopharmaceutical industries
to support analytical characterization, process development
and quality control of therapeutic recombinant monoclonal
antibodies (rmAbs). This method is based on the use of dif-
ferent sieving matrices as background electrolytes [22]. SDS–
PAGE has been used for over four decades [23, 24] and it
is still commonly used for protein separation in many lab-
oratories. This technique suffers, however, from a lack of
repeatability, probably because of many manual operations
(sample loading, staining . . . ). It is also a time-consuming
and labor-intensive technique. CE technology encompasses
those issues by bringing advantages like an enhanced preci-
sion, the use of smaller quantities of reagent and an on-line
quantitative detection by UV or by LIF detection for high
sensitivity. Moreover, CGE has a high resolving power and
high throughput. It also provides automated operation allow-
ing a significant gain of time for the analyst, while avoid-
ing the bias and errors linked to the different steps relative
to SDS–PAGE technique. Using CGE it is also possible to
have a more accurate protein quantification [25] and pre-
cise molecular weight (MW) determination [26–31]. More-
over the CE system can be coupled with different kinds of
detectors, including the laser-induced fluorescence (LIF) de-
tector that is particularly interesting in terms of sensitivity and
selectivity [32–36].
The goal of this study was to follow amolecule of biomed-
ical interest. To achieve this goal, a CGE method coupled
to LIF was developed to separate and quantify the differ-
ent oligomeric species of aSyn protein formed in vitro. For
this purpose, the reliability of the analytical system had to
be checked, so repeatability and intermediate precision were
evaluated. Importantly, the stability of aSyn solutionswas also
investigated. It is worth noting that the robustness of the CGE
method was already demonstrated [37–39]. But in the context
of this study devoted to the analysis of potentially unstable
molecules having a biomedical interest, it was important to
demonstrate that the conditions were appropriate. Then, dif-
ferent labeling agents were screened in order to obtain sen-
sitive LIF detection, and the labeling process was optimized
by testing different derivatizing agent/protein ratios, among
other parameters. All the results obtained by CGE–LIF were
compared to those acquired by SDS–PAGE using the same
samples. Since the developed CGE–LIF method is able to
separate the different species of the protein, it also allows
to calculate the oligomeric/total form species ratio. Finally,
this method was applied to study the impact of compounds
on the oligomerization process. As doxycycline is described
to decrease the number of aSyn oligomers, the effect of
this compound was evaluated using the optimized CGE–LIF
method.
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2 Material and methods
2.1 Chemicals and reagents
Ultrapure water was supplied by a Milli-Q equipment
(Millipore, Bedford, MA, USA) and Chromafil syringe filters
(0.20 m) were obtained from Macherey-Nagel (Duren, Ger-
many). Dimethylsulfoxyde (DMSO), NH4OH, borate buffer,
sodium acetate and acetic acid were purchased from VWR
(Leuven, Belgium). PBS was obtained from Lonza (Basel,
Switzerland) and corresponds to a pH 7.4 phosphate buffer
(9.5 mM). A pH 8.0 borate buffer was prepared by using
chemicals from Merck (Darmstadt, Germany). 4-fluoro-7-
nitrobenzofurazan (NBD-F), NHS-Fluorescein, Alexa Fluor
488 (NHS-ester) and ATTO-TAG CBQCA were purchased
from Thermo Fisher Scientific (Waltham, USA). Chromeo
P503 was from Santa Cruz Biotechnologies (Heidlberg,
Germany), and fluorescein isothiocyanate isomer I (FITC)
was from Merck (Darmstadt, Belgium). Doxycycline was
obtained from Sigma Aldrich (Saint-Louis, MO, USA). Re-
combinant human aSyn was produced in E. coli and purified
as described previously [40]. It was produced and purified at
the Center for Protein Engineering (CIP, University of Liege,
Belgium) and stored at –80°C under its lyophilized form.
2.2 CGE
The experiments were conducted using a G7100 CE system
(Agilent Technologies,Waldbronn,Germany), equippedwith
an autosampler and a temperature control system. In order to
use the CE+pmode (Capillary Electrophoresis mode with us-
age of higher pressure), an external pressure provided by an
oil-free air supply systemwas added. The CGEmethod condi-
tions described below were adapted from Nunnaly et al. [37],
for the equipment used. The detection was carried out using
an online diode array detector and a laser-induced fluores-
cence (LIF) detector. UV detection was set at 200 and 214 nm.
The LIF detector was purchased from Picometrics Technol-
ogy (Labe`ge, France), and is composed of laser diodes with
a continuous constant-amplitude output (or CW, continuous
wave). It was used at an excitationwavelength of 488 nm. Bare
fused-silica capillaries with an internal diameter of 50 m
were obtained from Optronis (Kehl, Germany). Capillaries
of 33 cm total length (8.5 and 20.5 cm effective length for
UV and LIF detection, respectively) were used. Experiments
were performed using the outlet injection mode unless oth-
erwise stated. Samples were injected hydrodynamically by
applying a pressure of −100 mbar during 100 s. After injec-
tion, a voltage ramp was generated during 1.6 min to reach
the voltage of 16.5 kV in a normal polarity mode. During the
migration (run of 30 min), a two bar pressure was applied to
both inlet and outlet vials in order to avoid foam formation,
and the capillary was thermostated at a temperature of 25°C.
The background electrolyte (BGE, also called SDSGel Buffer)
used for all analyses was purchased from Beckman Coulter
(Brea, CA, USA). Once a day, capillaries were conditioned
as follows: high pressure flush at 2 bar with 0.1 M NaOH
for 10 min, with 0.1 M HCl for 5 min and with water for
2 min, and high pressure flush at 4 bar with SDS Gel Buffer
for 10 min. Prior to each run, capillaries were conditioned as
follows: high pressure flush at 4 bar with 0.1 M NaOH for
3 min, with 0.1 M HCl for 1 min, with water for 1 min and
with SDS Gel Buffer for 10 min. Under these running condi-
tions, a MWmix composed of proteins with known sizes was
injected at the beginning of each sequence. AMW calibration
curve was constructed, and a logarithmic regression with a
determination coefficient of 0.99 (r2) was obtained.
Prior to CGE analysis, all samples were directly trans-
ferred in polypropylene microvials, without the addition of
any reducing agent, meaning they are analyzed by CGE un-
der non-reducing conditions. Also, at the beginning of each
sequence, a QC is injected to guarantee the reliability of the
followed results.
2.3 SDS–PAGE
SDS–PAGE was used in parallel with the CGE separation
method. NuPAGE R© Bis-Tris 12% gel and Mark 12, used
as MW marker, were provided by Thermo Fisher Scien-
tific (Waltham, MA, USA). The protein migration took place
in MOPS buffer (Thermo Fisher Scientific), and the elec-
trophoretic profiles were revealed using SYPRO R© Ruby pro-
tein gel stain, purchased from Thermo Fisher Scientific.
The fluorescence was detected with an Amersham Im-
ager 600 RGB (GE Healthcare, Chicago, IL, USA), contain-
ing CDD optics from Fujifilm (Tokyo, Japan). The data were
processed with ImageQuant TL Software by using the 1D
gel analysis module, where a lane in the image represents
each sample. The analysis assesses the amounts of separated
components from the integrated intensity of bands, and the
volume quantitation (integrated intensity) of the bands is cal-
culated from the area under the average lane profile and the
width of the lane. The method uses a line spanning the width
of a gel lane to generate a profile from the average signal at
each row of pixels perpendicular to the line. Prior to SDS–
PAGE analysis, only NuPAGE LDS sample buffer (4X) was
used. Ultrapure water was added if it was necessary to adjust
the final concentration of aSyn at 10 M.
2.4 aSyn stability in solution
After production, the identity of the protein was confirmed by
Q-TOFmass spectrometry before the experiments performed
by CGE, with a spectrum with an absorption maximum at
280 nm. Three different media were tested to evaluate the
aSyn stability: a 0.16%NH4OH solution, ultrapure water, and
PBS. The aSyn solutions were prepared at a concentration of
2 mg/mL (140 M) in Protein LoBind microcentrifuge tubes
(Eppendorf, Hamburg, Germany) and left without agitation
at room temperature. Aliquots were taken at different times:
4–16–28–40–216 h, and they were analyzed by CGE–UV.
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Table 1. (A) Evaluation of the method repeatability with CGE–UV and SDS–PAGE. (B) Evaluation of intermediate precision with CGE–UV.
The areas of the CGE–UV for each protein was corrected by the area of the 10 kDa protein
% 14.4 kDa 20 kDa 35 kDa 50 kDa 66.6 kDa 100 kDa 150 kDa 225 kDa
(A) REPEATABILITY (n = 6)
Volume (SDS–PAGE) 4.0 3.1 4.7 9.2 6.5 5.9 8.7 10.5
Corrected area
(CGE–UV) 0.4 0.4 1.1 0.6 0.7 1.1 2.6 2.0
Migration time
(CGE–UV) 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2
(B) INTERMEDIATE PRECISION (n= 3; k = 3)
Corrected area
(CGE–UV) 0.4 1.1 2.4 2.1 1.5 2.7 2.8 2.4
Migration time
(CGE–UV) 0.4 0.4 0.4 0.5 0.5 0.5 0.6 0.6
To evaluate the effect of freeze-thaw cycles in 0.16%
NH4OH solution, a 2 mg/mL aSyn solution was tested over
five cycles. Aliquots were then analyzed by CGE–UV and
SDS–PAGE.
2.5 aSyn derivatization
After careful screening and optimization of vari-
ous labeling reagents (Chromeo P503, NBD-F, NHS-
Fluorescein, Alexa Fluor 488 (NHS-ester), ATTO-TAG
CBQCA and FITC (Supporting Information Fig. 1)),
NBD-F was chosen as labeling agent. A stock solution
of 10 mM NBD-F in DMSO was prepared, aliquoted
in amber microcentrifuge tubes (Eppendorf, Hamburg,
Germany) to protect it from light, and stored at –80°C. All
the reactions were performed under inactinic light in am-
ber microcentrifuge tubes. The labeling process consisted
of the addition of a 10 mM NBD-F solution and aSyn into
a borate buffer (50 mM, adjusted at pH 8.0) at a ratio of
15:1 (NBD-F:aSyn), corresponding to a final concentration of
150 M and 10 M of NBD-F and aSyn, respectively. The
solution was then heated at 30°C during 90 min under gentle
agitation.
2.6 aSyn oligomerization
The impact of doxycycline on aSyn oligomerizationwas inves-
tigated. A 20 mM stock solution of doxycycline was prepared
in ultrapure water. aSyn was incubated at a concentration of
5 M in a 500 M doxycycline solution (prepared in borate
buffer), so that the aSyn:doxycycline ratio was 1:100.
3 Results and discussion
3.1 CGE versus SDS–PAGE performance
SDS–CGE requires a sieving matrix as BGE to separate the
proteins according to their size, and a commercial gel from
Beckman Coulter was used for this purpose. The repeatabil-
ity and the intermediate precision of the CGE method were
evaluated in terms of corrected peak area and migration time
RSDs obtained following the injection of a reference mixture
of nine proteinsmarkers having awide range ofMW (from10
to 225 kDa) (Table 1). The area of each protein was corrected
by the area of the 10 kDa protein. As shown in this Table, the
migration times of the proteins in CGE were found to be very
stable (RSDs0.1%). The same protein mixture was also an-
alyzed by SDS–PAGE using SYPRO R© Ruby staining, and the
volume of each bandwas evaluated (Table 1). A bettermethod
repeatability was observed in CGE–UV (RSDs for corrected
peak area from 0.4 to 2.6%) compared to SDS–PAGE (RSDs
for band volume from 3.1 to 10.5%).
Regarding the intermediate precision of the CGE
method, low RSD values were obtained for corrected peak
areas (between 0.4 and 2.8%) and for migration times (be-
tween 0.4 and 0.6%) (Supporting Information Fig. 1). These
results indicate a good repeatability and intermediate preci-
sion for the CGEmethod therefore based on a well character-
ized method, it can be applied on our protein of interest.
3.2 aSyn stability in solution
The stability of a protein is an important parameter to be
considered. It is particularly true for aSyn, as it is capable of
self-assembly under certain conditions. Different factors can
affect the stability, and the solution in which the protein is
dissolved is an important one. In a previous study on amyloid
ß1-42-peptides, researchers found that the presence of 0.16%
NH4OH dramatically slowed down the oligomerization
process [41]. As aSyn is also an amyloid protein intrinsically
unfolded, we tested a 0.16% NH4OH solution as well as
ultrapure water, PBS and a pH 4.0 acetate buffer. The
latter has been described to promote the oligomerization
process [42]. The samples were analyzed by CGE–UV, and
for comparison, the percentage of the monomeric form
regarding the total amount of the protein was considered.
Figure 1 reports the evolution of this percentage as a function
of time. After 12 h, incubation into 0.16% NH4OH solution,
C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 1. Evaluation of aSyn
monomer stability in different
media by CGE–UV. A 2 mg/ml
solution was prepared in differ-
ent media: 0.16% NH4OH solu-
tion, ultrapurewater, PBS and pH
4.0 acetate buffer.
ultrapure water and PBS, more than 95% of aSyn was
monomeric indicating a good stability; instead in pH 4.0
acetate buffer only 82% of the protein was still monomeric.
After 216 h, 88% of the protein remained monomeric in
0.16% NH4OH solution, 80% in ultrapure water and 74%
in PBS. Only 48% remained monomeric in pH 4.0 acetate
buffer, which is in good agreement with the potential of
this solution to promote aggregation [42]. As aSyn in 0.16%
NH4OH showed the highest stability over time, this solution
was used for further experiments. Supporting Information
Fig. 2 represents the overlay of the electropherograms in
the different tested media, at T0 (Supporting Information
Fig. 2A), and after 9 days (216 h, Supporting Information
Fig. 2B). At T0, the only peak observed corresponds to the
MW of aSyn monomer. Whatever the medium composition,
the peak is sharp, without any degradation or oligomerization
product, corresponding to 100 % of the monomeric form.
These peaks were compared to those obtained with samples
after 216 hours of incubation (Supporting Information
Fig. 2B). As shown in this figure, degradation products,
having a lowerMW,migrate faster than themonomeric peak,
in all tested solutions. The electropherograms observed in
the Supporting Information Fig. 2B had a range of migration
time from 5.5 to 9.0 min for acidic conditions, corresponding
to molecular sizes from 9.2 to 82 kDa. As can be seen in
the electropherogram, the species observed directly after
the monomeric peak could be composed of fragments plus
monomer and/or oligomeric species of aSyn. Those products
were observed in ultrapure water and especially in pH 4.0
acetate buffer, giving rise to a large peak that probably
includes different MW species. A stock solution of aSyn in
0.16% NH4OHwas frozen at −80°C to avoid a too fast degra-
dation of the protein. The stability of the protein after five
freeze-thaw cycles was tested in CGE–UV and SDS–PAGE
(data not shown). No significant difference in monomeric
form abundance was observed using both approaches, even
after five cycles.
3.3 Optimization of aSyn derivatization
Since aSyn has no tryptophan residue its intrinsic fluores-
cence is low; and furthermore the amino acid sequence is
composed of 4 tyrosine, corresponding to 2.9% in terms of
its entire sequence. The native fluorescence of aSyn was eval-
uated (at 266 nm), but the sensitivity was not sufficient to fol-
low the oligomerization products. That is why an increased
sensitivity was needed, and to do this the derivatization of
the protein by the use of a labeling agent was considered
in order to enable the use of LIF detection and achieve bet-
ter sensitivity compared to UV detection. More than 10% of
aSyn are lysine residues (15 out of 140 amino acids), corre-
sponding to 15 primary amines. Therefore, different amine-
reactive labeling agents were considered: FITC, Chromeo
P503, NHS-fluorescein, Alexa Fluor 488 (NHS ester), ATTO-
TAG CBQCA and NBD-F. All these reagents were chosen
because they have an excitation wavelength compatible with
the use of a 488 nm laser.
Preliminary experiments showed that NBD-F gave the
best compromise between sensitivity and background noise
(Supporting Information Table 1). This compound is a fluo-
rogenic labeling agent that reacts with primary and secondary
amines in alkaline medium (pH around 8 and 9) [43,44]. The
detection limit with NBD-F was previously found to be of
25 ng/mL for BSA with a labeling ratio of 1:150 (BSA:NBD-
F), which is much lower than with other detection techniques
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Figure 2. (A) Comparison of two electropherograms: blank samplewith NBD-F in red, showing only one peak corresponding to free NBD-F
at a migration time of 7.55 min. In blue, aSyn sample derivatized with NBD-F showing a peak corresponding to free NBD-F (7.55 min), and
labeled aSyn (14.8 min). (B) and (C): analysis of an aggregated aSyn sample by CGE–LIF (B) and SDS–PAGE (C). The method conditions
for the CGE–LIF were as followed: hydrodynamic injection by applying a pressure of −100 mbar during 100 s. A voltage of −16.5 kV was
then applied. The capillary had an effective length of 20.5 cm, thermostated at 25°C. LIF was set with an excitation wavelength of 488 nm.
such as Coomassie blue staining (2500 ng/mL) and UV–
visible detection in SDS–CGE (500 ng/mL) [45].
It is worth mentioning that an appropriate buffer has to
be used to provide a high labeling yield while avoiding label-
ing reagent hydrolysis [42]. Therefore, the composition of the
reaction buffer had to be optimized for each tested labeling
agent. Moreover, the concentration ratio of the labeling agent
to the protein had also to be carefully optimized, since a too
large excess of the reagent can lead to a high background
noise and interferences during the separation.
In this study, as the goal was to obtain the best sen-
sitivity, and since the peaks efficiency and the background
noise values were similar for the different tests performed,
only the peak areas were taken into consideration. In a
first step, three buffers were tested, with different pH val-
ues: bicarbonate buffer (100 mM, pH 8.3), phosphate buffer
(20 mM, pH 7.5), and borate buffer (50 mM, pH 7.5–8–
8.5–9–9.2, see Supporting Information Fig. 3B). The borate
buffer adjusted at pH 8.0 was found to be the most appropri-
ate, as it gave the highest peak areas compared to the other
buffers.
Different incubation times were tested, namely 30, 60,
90, 120 and 150 min. Compared to other conditions, the
incubation time of 90 min gave higher peak areas, (Support-
ing Information Fig. 3C), so an incubation of 90 min was
chosen. The effect of the temperature of the labeling reaction
was also evaluated at room temperature, 30°C or 60°C, and
compared to other conditions, the temperature of 30°C gave
higher peaks areas (Supporting Information Fig. 3A), which
was therefore selected. In conclusion, the labeling reaction
with NBD-F had to be performed in borate buffer (50 mM,
pH 8.0), during an incubation time of 90 min, at a
temperature of 30°C and under 600 rpm agitation. Figure 2A
illustrates the electropherograms obtained after the labeling
reaction in the optimized conditions, compared with a blank.
Two well-separated peaks corresponding to the free labeling
agent and labeled aSyn are mainly observed in the sample
solution. Small peaks present before the main peak corre-
spond to degradation products, and the small peak observed
after the peak corresponds to a dimeric form, which are often
observed in all conditions. The presence of degradation and
dimeric forms are also observed when samples are analyzed
by SDS–PAGE. The NBD-F:aSyn ratio being also a critical
parameter, different ratios from 5:1 to 25:1 were tested.
Figure 3 represents the results obtained (n= 3) by comparing
the peak areas of the monomeric aSyn at the different ratios.
The peak area obtained at a ratio of 5:1 was much lower
than those found at the other ratios, probably because of
an incomplete labeling reaction due to a too low quantity of
reagent. Over labelling a protein can cause quenching due
to dye to dye interactions, but it can also decrease solubility
leading to precipitation and to a quenching of the fluorescent
signal [46]. Here, the best results in term of peak area of
labeled aSyn were obtained at a 15:1 ratio.
3.4 Stability of NBD-F labeled aSyn
After the selection of NBD-F as labeling agent, the stability of
the labeled samples was evaluated by taking into account the
peak areas. Labeled aSyn has to be stable over time, to allow
its analysis in a sequence of multiple samples.
A sample of 5 M labeled aSyn was analyzed by CGE–
LIF over a 20 h period. Six injections of the same sample
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Figure 3. Optimization of the NBD-F:aSyn ra-
tio. Different ratios were tested between 5:1 and
25:1 (n = 3, mean ± SD).
were made during this period (approximately one injection
every 3 h). The values were distributed around the average,
and the peak area RSD value for monomeric aSyn was found
to be 6.6%. Moreover, the bias between the first and the last
injection was 10%, which indicates a satisfactory stability of
the labeled aSyn during at least 20 h.
3.5 Labeled aSyn quantitation
aSyn has been shown to be present in healthy control groups
as a normal CSF constituent in the low ng/mL concentration
range (from 27 to 32 pM) [16]. It is also found in blood (in-
cluding plasma and serum) under physiological conditions at
a level up to tenfold higher than in CSF, and in whole blood
lysates at a level up to 10,000-fold higher [16, 47]. This large
amount in whole blood is due to the fact that aSyn is highly
expressed in the hematopoietic system [48]. aSyn was also
found in neuronal synapses at a physiological concentration
of about 0.7 mg/mL (48 M) [49].
A calibration curve from 0.5 to 50 M of labeled aSyn
was carried out using the optimized CGE–LIF method.
To perform this calibration curve, independent triplicates
at each concentration were prepared and analyzed. A de-
termination coefficient (r2)  0.99 was obtained. A RSD
value of 20% was obtained at the lowest concentration
(0.5 M), whereas it was 10% at the other concentration
levels.
As mentioned in Section 1, the lowMW aSyn oligomeric
species seem to play an important role during the develop-
ment of PD. To date, only few ELISA studies [8–15] reported
measurements of aSyn oligomers. Nevertheless, some fac-
tors can affect the signal obtained using this technique, re-
sulting in variations in protein measurements. Furthermore,
depending on the oligomers studied, the answer will not be
the same, so for a specific oligomeric form, ELISA requires
aSyn standards having the same oligomeric state, which is
very unlikely.
The next step of this study consisted of evaluating the
ability of the optimized CGE–LIF method to monitor the
presence of lowMW oligomers individually. A solutionmade
up of different small oligomeric species was analyzed by
CGE–LIF and SDS–PAGE (Figure 2B and C). The electro-
pherogram (Figure 2B) shows that besides the monomeric
aSyn (1X), other smaller peaks corresponding to oligomeric
species, from dimers (2X) to hexamers (6X) are present. Their
MW was assessed by the mix of MW standards. SDS–PAGE
(Figure 2C) analysis was also performed on the same samples
and several bands corresponding to the monomeric species
and the oligomeric forms were observed. A S/N ratio of 16
was calculated for the oligomeric species having the low-
est S/N for comparable background noise (corresponding
to the hexameric form), indicating that the different species
frommonomeric could be quantified aftermethod validation.
These are very promising results, showing the potential of the
CGE–LIF method to separate the different species present in
a sample. Since no standard of oligomeric species exists, rel-
ative quantification was performed taking into account the
normalized ratio of the oligomeric species level to the total
forms aSyn concentration.
In view of the perspectives offered by this method, an in-
teresting application is tomonitor the potential effect of some
compounds on the oligomerization of aSyn. More precisely,
this CGE–LIF method could be used to evaluate inducers or
inhibitors compounds influencing the oligomerization pro-
cess. With this aim in view, a preliminary experiment was
carried out by incubating a solution of aSyn with doxycycline
and analyzing it by CGE–LIF after different incubation times,
from 0 to 96 h. The normalized oligomers/total forms ratios
were calculated, taking into account the ratios at T0 and at
a given time. Figure 4 shows the normalized ratios obtained
for the samples with and without doxycycline, at 0, 24, 48 and
96 h. In the presence of doxycycline, a lower ratio was ob-
served at each incubation time, compared to the control solu-
tion. These observations indicate a decrease of the concentra-
tion of lowMWaSyn oligomeric specieswhile themonomeric
C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 4. Comparison of nor-
malized ratios of aSyn samples
after different incubation times
(0–24–48–96 h) with or without
the addition of doxycycline. A ra-
tio of 1:100 (aSyn:Doxycycline)
was used in this experiment.
species concentration remains rather stable. These results
are in agreement with those obtained by Gonza´lez-Liza´rraga
et al. [50], who observed in the presence of doxycycline a
reshape of aSyn oligomers into off-pathway and high MW
species that do not evolve into fibrils. These species present a
less hydrophobic surface than the on-pathway oligomers, and
they were found to reshape towards non-toxic parallel beta-
sheet structured forms [50]. This experiment demonstrates
the great interest of the developed CGE–LIF method regard-
ing the study of aSyn behavior in the presence of potentially
therapeutic agents.
4 Concluding remarks
In this paper, we described the development of a fast CGE–
LIF method to monitor different aSyn species (i.e. monomer
and oligomers). The use of a well-known technique such as
SDS–PAGEhelped us to support the results obtained byCGE.
The developedmethod presents advantages over SDS–PAGE:
it is an automated method, giving qualitative and quantita-
tive data about aSyn species, which is very interesting since
specific oligomeric species are toxic. The repeatability and
the intermediate precision were evaluated based on a ref-
erence mix of proteins, having a wide range of MW from
10 to 225 kDa. Migration time RSDs 0.6% and peak areas
RSDs 2.8% were observed. Nowadays, the oligomerization
process is an important challenge to take up, and a better
understanding of such a mechanism would be a great help,
even if there is still a lot to do in that field. By following the
levels of different aSyn species, or by using concentration
ratios (oligomers to total forms), this innovative CGE–LIF
method could be a useful tool to evaluate different potentially
therapeutic agents, or to study different factors influencing
the oligomerization process in vitro. Preliminary experiments
were made with doxycycline, showing the potentiality of the
CGE–LIF method.
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